https://www.selleckchem.com/pr....oducts/n6-methyladen
mone axes, indicating severe disease. Prolactin elevation could suggest that a case of Sheehan's syndrome is severe. Target therapy with BRAF/MEK inhibitors in metastatic melanoma is characterised by a high response rate; however, acquired resistance to treatment develops in many cases. We aimed to investigate if baseline total metabolic tumour volume (TMTV) and therapy-response assessment by [ F]FDG PET/CT have a prognostic role on progression-free survival (PFS) and overall survival (OS) in patients with metastatic melanoma